Chairman David Chiswell takes over as Interim CEO
Christian Grøndahl has stepped down as Chief Executive of Kymab, a specialist in the development of monoclonal antibodies generated using its Kymouse discovery platform, owing to family commitments. David Chiswell, Chairman of the Cambridge, UK-based company, has taken over as interim CEO until a new CEO has been appointed.
Chiswell said: 'On behalf of the Board of Directors, I would like to thank Christian for his significant contribution to Kymab. Under his leadership, the company has successfully raised US$40m in a second funding round from the Wellcome Trust and the Bill and Melinda Gates Foundation, providing a strong foundation on which Kymab can enter its next stage of growth. We wish him every success in his next venture.'